These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37869082)

  • 1. Incessant ovulation: a review of its importance in predicting cancer risk.
    Cramer DW
    Front Oncol; 2023; 13():1240309. PubMed ID: 37869082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does "incessant" ovulation increase risk for early menopause?
    Cramer DW; Xu H; Harlow BL
    Am J Obstet Gynecol; 1995 Feb; 172(2 Pt 1):568-73. PubMed ID: 7856687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.
    Terry KL; Titus-Ernstoff L; McKolanis JR; Welch WR; Finn OJ; Cramer DW
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):30-5. PubMed ID: 17220329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime Number of Ovulatory Cycles and Risks of Ovarian and Endometrial Cancer Among Postmenopausal Women.
    Yang HP; Murphy KR; Pfeiffer RM; George N; Garcia-Closas M; Lissowska J; Brinton LA; Wentzensen N
    Am J Epidemiol; 2016 May; 183(9):800-14. PubMed ID: 27190045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cycle and hormone changes during perimenopause: the key role of ovarian function.
    Burger HG; Hale GE; Dennerstein L; Robertson DM
    Menopause; 2008; 15(4 Pt 1):603-12. PubMed ID: 18574431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles.
    Apter D; Vihko R
    J Clin Endocrinol Metab; 1983 Jul; 57(1):82-6. PubMed ID: 6222061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovulation and risk of epithelial ovarian cancer.
    Purdie DM; Bain CJ; Siskind V; Webb PM; Green AC
    Int J Cancer; 2003 Mar; 104(2):228-32. PubMed ID: 12569579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.
    Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS
    Menopause; 2009; 16(1):50-9. PubMed ID: 18978637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
    Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
    Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic analysis of breast and gynecologic cancers.
    Hulka BS
    Prog Clin Biol Res; 1997; 396():17-29. PubMed ID: 9108587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for epithelial ovarian tumours of borderline malignancy.
    Parazzini F; Restelli C; La Vecchia C; Negri E; Chiari S; Maggi R; Mangioni C
    Int J Epidemiol; 1991 Dec; 20(4):871-7. PubMed ID: 1800425
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.